Sotera Health to Share Next Chapter of Growth at 2024 Investor Day
Sotera Health Company (Nasdaq: SHC) announced its 2024 Investor Day in New York City, where management will present the company's strategic positioning and future growth plans. The company, which provides sterilization solutions and lab testing services, will outline its 2025-2027 financial plan targeting 5-7% organic revenue growth, 5-8% Adjusted EBITDA growth, and over $500 million in cumulative Free Cash Flow. Management will discuss their $18 billion serviceable addressable market and demonstrate the company's strength while fulfilling its Safeguarding Global Health® mission.
Sotera Health Company (Nasdaq: SHC) ha annunciato il suo Investor Day 2024 a New York City, dove la direzione presenterà la posizione strategica dell'azienda e i piani di crescita futura. L'azienda, che fornisce soluzioni di sterilizzazione e servizi di testing di laboratorio, delineerà il suo piano finanziario 2025-2027 con l'obiettivo di una crescita organica dei ricavi del 5-7%, una crescita dell'EBITDA rettificato del 5-8% e oltre 500 milioni di dollari di flusso di cassa libero cumulativo. La direzione discuterà del proprio mercato indirizzabile servibile da 18 miliardi di dollari e dimostrerà la forza dell'azienda mentre adempie alla sua missione di Safeguarding Global Health®.
Sotera Health Company (Nasdaq: SHC) anunció su Día del Inversor 2024 en la ciudad de Nueva York, donde la dirección presentará la posición estratégica de la empresa y los planes de crecimiento futuro. La empresa, que proporciona soluciones de esterilización y servicios de pruebas de laboratorio, esbozará su plan financiero 2025-2027 con un objetivo de crecimiento orgánico de ingresos del 5-7%, crecimiento del EBITDA ajustado del 5-8% y más de 500 millones de dólares en flujo de caja libre acumulado. La dirección discutirá su mercado direccionable servible de 18 mil millones de dólares y demostrará la fortaleza de la empresa mientras cumple su misión de Safeguarding Global Health®.
소테라 헬스 컴퍼니 (Nasdaq: SHC)는 뉴욕시에서 2024 투자자의 날을 발표하며, 경영진은 회사의 전략적 위치와 향후 성장 계획을 발표할 것입니다. 이 회사는 멸균 솔루션과 실험실 테스트 서비스를 제공하며, 2025-2027 재무 계획을 설명할 예정이며, 이를 통해 5-7%의 유기적 수익 성장, 5-8%의 조정 EBITDA 성장, 그리고 5억 달러 이상의 누적 자유 현금 흐름 목표를 세우고 있습니다. 경영진은 180억 달러의 서비스 가능 시장에 대해 논의하고, 글로벌 건강 보호® 사명을 수행하는 동안 회사의 강점을 보여줄 것입니다.
Sotera Health Company (Nasdaq: SHC) a annoncé son Investor Day 2024 à New York, où la direction présentera le positionnement stratégique de l'entreprise et ses plans de croissance futurs. L'entreprise, qui fournit des solutions de stérilisation et des services de tests en laboratoire, exposera son plan financier 2025-2027 visant une croissance organique des revenus de 5 à 7 %, une croissance de l'EBITDA ajusté de 5 à 8 % et plus de 500 millions de dollars de flux de trésorerie libre cumulé. La direction discutera de son marché adressable servable de 18 milliards de dollars et démontrera la force de l'entreprise tout en remplissant sa mission de Safeguarding Global Health®.
Sotera Health Company (Nasdaq: SHC) hat seinen Investorentag 2024 in New York City angekündigt, auf dem das Management die strategische Position des Unternehmens und die zukünftigen Wachstumspläne präsentieren wird. Das Unternehmen, das Sterilisationlösungen und Labortestdienstleistungen anbietet, wird seinen Finanzplan 2025-2027 skizzieren, der ein organisches Umsatzwachstum von 5-7%, ein bereinigtes EBITDA-Wachstum von 5-8% und über 500 Millionen Dollar kumulative freie Cashflows anvisiert. Das Management wird seinen marktfähigen adressierbaren Markt von 18 Milliarden Dollar erörtern und die Stärke des Unternehmens demonstrieren, während es seiner Mission, die globale Gesundheit zu schützen®, nachkommt.
- Targets 5-7% organic compound annual revenue growth for 2025-2027
- Plans to expand Adjusted EBITDA margins by at least 50 basis points
- Projects over $500 million cumulative Free Cash Flow generation
- Large serviceable addressable market of $18 billion
- Strong track record of top and bottom-line growth with robust margins
- None.
CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health’s management team will discuss the Company’s strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions.
“The management team is looking forward to the Company’s inaugural Investor Day since going public in 2020,” said Michael J. Petras, Jr., Chair and CEO. “During the past four years, we have achieved top- and bottom-line growth with strong margins, generated significant operating cash flow, demonstrated disciplined capital deployment, and maintained durable customer relationships. I’m proud of what we’ve accomplished and look forward to the team sharing more about future growth drivers at today’s investor event.”
During today’s presentation, management will:
- Demonstrate the strength and durability of Sotera Health while fulfilling our mission of Safeguarding Global Health®;
- Provide a detailed perspective of the markets served by the Company and growth opportunities, including our serviceable addressable market of
$18 billion ; - Share customer feedback, which will continue to guide capital investment decisions and the Company’s growth outlook;
- Provide a long-term financial outlook that highlights the focus on Free Cash Flow generation and supports a compelling investment thesis; and
- Outline our 2025-2027 financial plan to achieve an organic compound annual revenue growth rate of
5% to7% , expand Adjusted EBITDA margins by at least 50 basis points, drive an organic compound annual Adjusted EBITDA growth rate of5% to8% , and generate cumulative Free Cash Flow of more than$500 million .
The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort. The Company cannot reconcile its expected Adjusted EBITDA, Adjusted EBITDA margins, Adjusted EBITDA growth rate and Free Cash Flow without unreasonable effort because certain items that impact net income, earnings per share and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time, including uncertainties caused by changes to the regulatory landscape, restructuring items and certain fair value measurements, all of which are potential adjustments for future earnings.
Investor Day
A live webcast of the event will be accessible at Presentation & Events | Sotera Health. Virtual participants are encouraged to pre-register at this link and log in to the webcast approximately 5-10 minutes prior to the start of the event. A live question-and-answer session will follow management’s prepared remarks. Sotera Health intends to make the investor presentation for the event available concurrently with the start of the event. A replay of the video webcast will be available within 48 hours following the conclusion of the event at Presentation & Events | Sotera Health. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.
INVESTOR RELATIONS CONTACT
Jason Peterson
Vice President Investor Relations & Treasurer
IR@soterahealth.com
MEDIA CONTACT
Kristin Gibbs
Chief Marketing Officer
kgibbs@soterahealth.com
Source: Sotera Health Company
FAQ
What are Sotera Health's (SHC) revenue growth targets for 2025-2027?
How much Free Cash Flow does Sotera Health (SHC) expect to generate during 2025-2027?
What is Sotera Health's (SHC) serviceable addressable market size?
What is Sotera Health's (SHC) projected Adjusted EBITDA growth rate for 2025-2027?
